Profile: Stryker Corp (SYK)
7 Mar 2014
Stryker Corporation (Stryker), incorporated on February 20, 1946, is a medical technology company. Stryker offers a diverse array of medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products. The Company operates in three business segments: Reconstructive, MedSurg, and Neurotechnology and Spine. Its products include implants used in joint replacement, trauma, and spinal surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment, as well as other medical device products used in a variety of medical specialties. In the United States, its products are marketed directly to doctors, hospitals and other health-care facilities. Internationally, its products are sold in over 100 countries through Company-owned sales subsidiaries and branches, as well as third-party dealers and distributors. In 2012, the Company completed the acquisition of Surpass Medical, Ltd. (Surpass). Effective March 1, 2013, Stryker Corp acquired the share capital of Trauson Holdings Co Ltd. In December 2013, the Company announced that it has completed the acquisition of MAKO Surgical Corp.
Reconstructive products consist primarily of implants used in hip and knee joint replacements and trauma surgeries. Many of its technologically advanced reconstructive implants are suited to minimally invasive surgery procedures that are intended to reduce soft-tissue damage and pain while hastening return to function. The Company supports surgeons with technology, procedural development and specialized instrumentation as they develop new surgical techniques. In 2012, the Company launched Accolade II, the first hip stem with a Morphometric Wedge design, an evolution of the tapered wedge stem. The Company also launched the GetAroundKnee direct to consumer advertising campaign to convey the benefits of the single radius design of its Triathlon Knee System.
The Company competes with Zimmer Holdings, Inc. (Zimmer), DePuy Synthes Company, Biomet, Inc. and Smith & Nephew plc.
MedSurg products include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices as well as other medical device products used in a variety of medical specialties. In 2012, the Company launched System 7, the next generation of heavy duty surgical power tools. These tools are used in total joint procedures, such as hip and knee replacements, and offer the latest in advanced cutting technology. The Company also launched the 1488 HD 3-Chip Endoscopic Camera System, which utilizes advanced CMOS technology and optics to provide a clear bright image designed to enhance patient outcomes. In addition, the Company launched Power-LOADTM, its cot fastener system that lifts and lowers the cot into and out of ambulances, thereby reducing spinal loads and the risk of cumulative trauma injuries to emergency responders.
The Company competes with Medtronic, Inc., Conmed Linvatec, Inc., Aesculap-Werke AG, Smith & Nephew Endoscopy, ConMed Linvatec, Inc., Arthrex, Inc., Karl Storz GmbH & Co., Olympus Optical Co. Ltd., Hill-Rom Holdings, Inc. and Kinetic Concepts, Inc.
Neurotechnology and Spine
Neurotechnology and Spine products include a portfolio of products, including both neurosurgical and neurovascular devices. Its neurotechnology offering includes products used for minimally invasive endovascular techniques, as well as a line of products for traditional brain and open skull base surgical procedures, orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products, as well as minimally invasive products for the treatment of acute ischemic stroke.The Company also develops, manufactures and markets spinal implant products, including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. In 2012, the Company received 510(k) approval to market the Trevo Pro Retriever, its next generation clot removal technology that utilizes Stentriever Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.
The Company competes with Covidien and Micrus Endovascular, LLC, Medtronic Sofamor Danek, Inc and DePuy Spine, Inc.
2825 Airview Boulevard
KALAMAZOO MI 49002
Company Web Links
- Stryker fourth-quarter profit up on higher sales, lower tax
- UPDATE 1-Stryker 4th-quarter profit up on higher sales, lower tax
- Stryker fourth quarter net profit rises 43 percent
- UPDATE 1-Stryker to buy Patient Safety Technologies for $120 mln
- Stryker to buy Patient Safety Technologies for $120 million